NEW YORK – Inivata said today that it has signed a distribution agreement with IPS Genomix to provide its InVisionFirst-Lung and InVisionSeq liquid biopsy tests to cancer patients and partners in the Middle East and Africa.
Under the agreement, IPS Genomix — a part of Integrated Pharma Solutions — will facilitate patient access through both insurers and in the private pay market in the United Arab Emirates, Qatar, Kuwait, Bahrain, Lebanon, Jordan, Egypt, and the Kingdom of Saudi Arabia.
Inivata's tests are designed to detect actionable information about a patient's tumor via cell-free tumor DNA shed into the blood.
"We are delighted that IPS has selected Inivata and our highly-sensitive liquid biopsy tests for their customers and partners in the Middle East and North Africa. The agreement further highlights Inivata’s growing momentum and expands our geographical reach outside our core market of the US," Inivata CEO Clive Morris said in a statement.
Financial and other terms were not disclosed.